The company said, “Revolution Medicines (RVMD) expects full year 2025 GAAP net loss to be between $840 million and $900 million, which includes estimated non-cash stock-based compensation expense of between $115 million and $130 million. Based on the company’s current operating plan, the company projects that current cash, cash equivalents and marketable securities can fund planned operations into the second half of 2027.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- RVMD Upcoming Earnings Report: What to Expect?
- Trump Trade: New administration to invest $20B to build data centers
- Revolution Medicines price target raised to $71 from $65 at UBS